Draft Whole-Genome Sequences of Ciprofloxacin-Resistant Derivatives of a Bacillus anthracis ΔANR Strain Lacking pXO1 and pXO2 Plasmids

Tracey D Biggs; Mark A Karavis; Jacquelyn V Harris; Jessica M Hill; Robert C Bernhards; Lance B Price; Paul Keim; Bruce G Goodwin; Shanmuga Sozhamannan

doi:10.1128/MRA.00056-20

Draft Whole-Genome Sequences of Ciprofloxacin-Resistant Derivatives of a Bacillus anthracis ΔANR Strain Lacking pXO1 and pXO2 Plasmids

Microbiol Resour Announc. 2020 Apr 9;9(15):e00056-20. doi: 10.1128/MRA.00056-20.

Authors

Tracey D Biggs¹, Mark A Karavis¹, Jacquelyn V Harris¹, Jessica M Hill^{1

2}, Robert C Bernhards^{1

3}, Lance B Price⁴, Paul Keim⁵, Bruce G Goodwin⁶, Shanmuga Sozhamannan^{7

8}

Affiliations

¹ US Army Combat Capabilities Development Command, Chemical Biological Center, Aberdeen Proving Ground, Aberdeen, Maryland, USA.
² DCS Corporation, Alexandria, Virginia, USA.
³ Defense Threat Reduction Agency, Fort Belvoir, Virginia, USA.
⁴ Department of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
⁵ The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
⁶ Defense Biological Product Assurance Office, CBRND-EB, JPEO, Frederick, Maryland, USA.
⁷ Defense Biological Product Assurance Office, CBRND-EB, JPEO, Frederick, Maryland, USA shanmuga.sozhamannan.ctr@mail.mil.
⁸ Logistics Management Institute, Tyson, Virginia, USA.

Abstract

Mutants of an attenuated Bacillus anthracis (ΔANR) strain conferring increasing levels of ciproﬂoxacin resistance have been described. Here, we report the draft genome sequences of the parent strain (ΔANR pXO1^-, pXO2^-) and its derivatives conferring low (step 1; 0.5 μg/ml), medium (step 2; 8 to 16 μg/ml), and high (step 3; 32 to 64 μg/ml) levels of ciprofloxacin resistance.